United States · Financial press · Barron's
This Biotech Stock Is Up 291% From Its IPO Price. It’s On Pace for a Record Closing High.
Detailed summary
CG Oncology stock is on pace for a record closing high after ‘best case’ Phase 3 trial results for its bladder cancer treatment.
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.barrons.com)
